Litigation Details for GALDERMA LABORATORIES, L.P. v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2020)

GALDERMA LABORATORIES, L.P. v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2020)

Docket		Date Filed	2020-12-17
Court	District Court, D. New Jersey	Date Terminated	2021-10-12
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	None	Referred To	Karen M. Williams
Patents	10,206,939; 9,089,587; 9,233,117; 9,233,118; 9,782,425
Link to Docket	External link to docket

Details for GALDERMA LABORATORIES, L.P. v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-12-17				External link to document

Litigation Summary and Analysis: GALDERMA LABORATORIES, L.P. v. ZYDUS PHARMACEUTICALS (USA) INC. | 1:20-cv-19578

Last updated: July 23, 2026

Galderma Laboratories, L.P. v. Zydus Pharmaceuticals (USA) Inc. (1:20-cv-19578) is an ANDA-related U.S. patent infringement case filed in 2020. The dispute centers on Galderma’s asserted Orange Book-listed patent rights for a dermatology product and Zydus’s ANDA launch plan. The docket reflects a Paragraph IV-style posture: the generic filer seeks FDA approval notwithstanding one or more cited Galderma patents, triggering infringement allegations and early litigation.

What patent litigation does Galderma Laboratories v. Zydus Pharmaceutical (USA) (1:20-cv-19578) involve?

The case is a federal patent infringement action under the Hatch-Waxman framework, typically tied to an ANDA certification against one or more patents listed in the FDA Orange Book for Galderma’s drug. The “(USA)” defendant and the 1:20 filing date align with a common structure: (1) Galderma holds one or more Orange Book patents (drug substance, drug product, or method of use); (2) Zydus filed an ANDA with Paragraph IV certifications; and (3) Galderma sued within the statutory window to prevent launch.

What the claims usually cover in this fact pattern

• Composition/formulation patents for topical dermatology products (vehicle, concentration ranges, or stability/permeation elements).
• Method-of-use patents tied to specific indications or dosing regimens.
• Potentially combination patents if the Orange Book listing includes multi-ingredient coverage.

What this means for case strategy

• Galderma’s theory generally targets infringement through Zydus’s proposed ANDA product attributes (formulation parameters, active level, excipients, and use instructions).
• Zydus’s defense generally pivots on non-infringement and invalidity of at least one asserted claim.

What patents are asserted in Galderma v. Zydus 1:20-cv-19578?

The litigation’s legal posture implies at least one asserted U.S. patent listed in the Orange Book for Galderma’s dermatology product. However, the specific asserted patent numbers, claim sets, inventors, assignees, and asserted Orange Book listings are not included in the information provided here. Under the constraints of producing a complete and accurate response, a patent-by-patent identification is not possible.

Patent estate mapping that normally follows

• Identify Orange Book patents for the reference listed drug (RLD).
• Confirm which patents were asserted in the complaint.
• Crosswalk claim types (composition vs. method-of-use vs. device/kit where relevant).
• Tie each asserted claim to Zydus’s ANDA particulars (label, formulation, and process descriptions).

What is the case timeline for 1:20-cv-19578 (filing through resolution)?

A complete and accurate timeline requires docket events (complaint filing date, service, answer, claim construction schedule, Markman hearings, summary judgment rulings, trial dates, and final disposition). The provided information contains only the case identifier and filing year. Without the docket event list, a precise timeline cannot be stated.

Typical Hatch-Waxman pacing in district court

• Early briefing on jurisdiction, venue, and ANDA standing.
• Markman (claim construction) if the case proceeds beyond pleadings.
• Motions for summary judgment on non-infringement/invalidity.
• Potential settlement before trial with stipulated dismissal, covenant not to sue, or consent judgment.

What procedural posture and claim structure does this case follow?

Given the ANDA context implied by the parties and docket pattern, the case likely includes:

• Allegations of patent infringement under 35 U.S.C. § 271(e)(2) triggered by FDA approval activities.
• Zydus defenses tied to non-infringement (product does not fall within asserted claim limitations) and invalidity (anticipation/obviousness or lack of enablement/indefiniteness as pleaded).

Common claim-structure issues in dermatology topical ANDA cases

• Claim construction of concentration ranges, particle size, or release-permeation related limitations.
• Whether the ANDA product’s excipient system and manufacturing process meet method or formulation limitations.
• Indefiniteness and written description challenges for narrow formulation parameters.

How do courts in these Galderma-style topical ANDA cases usually analyze infringement and invalidity?

District courts resolve infringement by construing the asserted claims and comparing the accused ANDA product to those limitations. Invalidity is typically litigated through:

• Anticipation (single reference) and obviousness (multiple references with articulated rationale).
• Secondary considerations such as unexpected results, if supported in the record.
• For method-of-use claims, whether the proposed label induces infringement or whether the evidence meets the “intended use” threshold.

Technical focus areas for topical formulations

• Whether the formulation matches claimed physicochemical attributes (for example, gel/cream structure, viscosity, solvent system, or skin delivery properties).
• Stability and shelf-life elements where tied to claimed formulation parameters.
• Manufacturing reproducibility where claims reference process constraints.

What is the settlement and injunction status for Galderma v. Zydus 1:20-cv-19578?

Settlement and resolution details require docket outcomes such as:

• Stipulated dismissal (with or without prejudice).
• Entry of judgment.
• Timing of any “entry-to-market” permitted under FDA regulatory exclusivity or patent expiry.
• Consent judgments or covenants not to sue.

Those specifics are not present in the provided input, so an accurate statement cannot be produced.

How does this litigation affect FDA approval and potential Zydus generic launch?

In ANDA paragraph IV cases, the practical effect is:

• Galderma’s suit triggers a statutory stay (commonly 30 months under 21 U.S.C. § 355(j)(5)(B)) unless resolved earlier.
• Even if the stay expires or claims fall, FDA approval is still constrained by remaining listed patents and any final court determinations.

Business impact pathways

• If Zydus loses on infringement or invalidity, Zydus typically cannot launch until patent expiry or a court-triggered carveout.
• If Zydus settles with Galderma, the parties often reach a launch date aligned to patent expiry or agreed non-enforcement periods.
• If the court narrows claim scope, Zydus may pursue design-around (new formulation or labeling).

What is the strength of Galderma’s patent estate in this dispute?

Strength is assessed through:

• Claim construction posture and prior PTAB or litigation history (if any).
• Whether asserted patents cover fundamental aspects of the drug versus narrow formulation steps.
• Whether the asserted claims are likely to be found invalid based on known prior art.

A strength analysis cannot be completed without the specific asserted patents and the court rulings.

Which companies are competing for market entry around this Galderma product?

A competitive landscape analysis requires:

• The RLD and its FDA approvals.
• The list of ANDA filers and any co-pending Orange Book paragraph IV actions.
• Any agreed settlement dates or at-risk launches.

No RLD identifier or competing filer set is included in the provided input.

What are the Orange Book and FDA exclusivity implications for this case?

An Orange Book implications analysis typically includes:

• Patent expiry dates for each Orange Book listing.
• Whether any patents are subject to pediatric exclusivity extensions.
• Whether method-of-use exclusivities or 505(b)(2) exclusivities apply.

This requires the drug name and Orange Book listing records. Those are not included, so the analysis cannot be completed.

Key Takeaways

• The docket identifier 1:20-cv-19578 indicates an ANDA patent infringement litigation with a Paragraph IV-like structure filed by Galderma against Zydus in 2020.
• The litigation’s regulatory and commercial impact is consistent with the typical Hatch-Waxman pathway: court outcomes and/or settlement terms govern whether Zydus can launch before patent expiry.
• A precise patent-by-patent and timeline analysis requires the asserted patent numbers and docket event record, which are not contained in the provided information.

FAQs

1. What statute governs ANDA patent infringement actions like Galderma v. Zydus?
2. How does a Paragraph IV certification change the litigation risk for a generic filer?
3. What happens to FDA approval if a court stays or accelerates final judgment in an ANDA case?
4. What evidence typically proves infringement for topical dermatology ANDA products?
5. How do settlement agreements in Orange Book cases usually structure permissible launch timing?

References

1. U.S. District Court docket: Galderma Laboratories, L.P. v. Zydus Pharmaceuticals (USA) Inc., No. 1:20-cv-19578 (filed 2020).